Pain Therapeutics, Inc. (PTIE) Hits All-Time Low at $2.14 on Jun, 29

June 29, 2018 - By Norman Soto

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. Barchart.com announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

PTIE is touching $2.14 during the last trading session, after decreased 5.10%.Pain Therapeutics, Inc. is uptrending after having risen 133.72% since June 29, 2017. PTIE has 274,326 volume or 132.03% up from normal. PTIE outperformed the S&P500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news brought out recently go to: Nasdaq.com, Schaeffersresearch.com, Nasdaq.com, Benzinga.com or Benzinga.com. The titles are as follows: “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” brought out on June 27, 2018, “3 Stocks Sinking in Afternoon Trading” on June 22, 2018, “Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER” with a publish date: June 26, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” and the last “20 Stocks Moving In Thursday’s Pre-Market Session” with publication date: June 28, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The company has $14.76 million market cap. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: